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Saudi Journal of Ophthalmology (2013) 27, 55–57Case ReportAcute bacterial endophthalmitis after intravitreal bevacizumab
injection: Case report and literature reviewSaba Al Rashaed, MD ⇑; Abdulaziz Rushood, MDAbstractA case report of a 52 year old male who received intravitreal bevacizumab and developed culture positive endophthalmitis. Vit-
reous culture indicated that endophthalmitis was caused by Staphylococcus epidermidis. The patient was initially managed with
intravitreal injection of ceftazidime and vancomycin, followed by pars plana lensectomy, pars plana vitrectomy with intravitreal
injection of 1 mg/0.1 ml vancomycin, 2.25 mg/0.1 ml ceftazidime, 5 mg/0.1 ml fortified amphotericin-B and 4 mg/0.1 ml dexa-
methasone. Postoperatively the patient improved significantly. However, vision improved from hand motion to counting fingers
secondary to severe retinal ischemia. Acute endophthalmitis can develop after intravitreal bevacizumab injections and cause pro-
found visual loss. A review of literature was also performed for similar cases.
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The introduction of vascular endothelial growth factor
antagonists has lead to a dramatic increase in intravitreal
injections worldwide. Currently the most common intravitreal
injections are performed with triamcinolone acetonide, bev-
acizumab (Avastin; Genentech Inc., San Francisco, CA,
USA) and ranibizumab (Lucentis; Genentech Inc., San Fran-
cisco, CA, USA) for a variety of conditions including exudative
age related macular degeneration (AMD) and macular ede-
ma of various etiologies.1–5
Complications after intravitreal injection include infectious
and sterile endophthalmitis, rhegmatogenous retinal detach-
ment, a transient increase in intraocular pressure and iatro-
genic injury to the eye.1–5 Infectious endophthalmitis is a
rare complication of intravitreal injection, but is relevant
due to the increased frequency and number of injections
being performed. Clinically, endophthalmitis can cause pro-Peer review under responsibility
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prompt and appropriate management.
In this case report we present a case of acute endophthal-
mitis after intravitreal injection of bevacizumab for prolifera-
tive diabetic retinopathy with macular edema that resulted
in with poor vision despite prompt management. We also
performed a literature review of similar cases of
endophthalmitis.
Case report
A 52 years old insulin dependent male diabetic was pre-
sented to the emergency room with loss of vision, pain,
and redness in his left eye. Three days prior to presentation,
the patient received an intravitreal injection of bevacizumab
elsewhere for diabetic macular edema. Ophthalmic
examination revealed visual acuity was 20/80 in the right
eye and hand motion in the left eye. There were no significantProduction and hosting by Elsevier
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Figure 1. Progress of an eye that underwent intravitreal bevacizumab injection and subsequently developed culture positive endophthalmitis. (A) At
presentation, 48 h after intravitreal injection showed no improvement with ciliary vessel injection, hypopyon and absence of a red reflex. (B) Three days
after the surgery. Note the disorganized hypopyon with corneal edema. (C) Two weeks after surgery showed a quiet eye and remnants of a disorganized
hypopyon. (D) Two months follow up showed central corneal haze with a quiet eye and resolution of the hypopyon.
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diabetic retinopathy. The left eye had marked lid edema with
ciliary injection, corneal edema with a 3 ml hypopyon, poster-
ior synechia and a white fundus reflex.
B-scan showed marked vitreal and subvitreal opacities
with diffuse retino-choroidal layers. The patient was diag-
nosed with acute endophthalmitis after intravitreal bev-
acizumab. An urgent vitreous tap was performed along
with intravitreal injection of vancomycin and ceftazidime.
The patient was placed on oral moxifloxacin once a day
and instructed to instill topical fortified cephalexin and ceft-
azidime drops hourly. Two days later, there was no clinical
improvement. The patient underwent synechiolysis, pars
plana lensectomy, pars plana vitrectomy with intravitreal
injection of 1 mg/0.1 ml vancomycin, 2.25 mg/0.1 ml ceftazi-
dime, 5 mg/0.1 ml amphotericin-B and 4 mg/0.1 ml dexa-
methasone. Postoperatively there was significant clinical
improvement. However, the vision improved from hand mo-
tion to counting by fingers secondary to severe retinal ische-
mia caused by the disease process. Fig. 1 presents the
progress of the eye from presentation onward. A culture
from the vitreous sample was positive for Staphylococcus
epidermis.
Discussion
Bevacizumab (Avastin) is a recombinant humanized full
length monoclonal antibody which binds to all biologically
active isoforms of a key mediator of angiogenesis – vascular
endothelial growth factor A (VEGF A). Bevacizumab has been
used off label to treat neovascular age related macular
degeneration (AMD) since 2005.3,6–9 Several groups have re-
ported the use of intravitreal bevacizumab for a number of
posterior segment conditions including central retinal vein
occlusion in proliferative diabetic retinopathy,10–19 pseud-ophakic cystoid macular edema,20 iris neovascularization,
neovascular glaucoma and diabetic macular edema.21–27
The incidence of (sterile or infectious) endophthalmitis re-
ported in most studies remains rare. For example, Fung
et al.28 analyzed 7113 cases of intravitreal bevacizumab
worldwide and found 1 case (0.01%) of endophthalmitis.
However Fung et al. did not differentiate between sterile
and infectious endophthalmitis. We believe the outcomes
from Fung et al’s28 and similar studies may underestimate ad-
verse events due to survey design, specifically the self report-
ing of complications.
The development of infectious endophthalmitis after an
intravitreal bevacizumab injection has been previously re-
ported. Fintak et al.1 reported an incidence of 0.02% for
infectious endophthalmitis following 12,585 cases of intravi-
treal bevacizumab. Two of the cases were caused by Strepto-
coccus viridans and one by S. epidermidis.1 All cases in Fintak
et al’s1 study ended with hand motion vision.1 The incidence
of endophthalmitis following intravitreal bevacizumab injec-
tion in a large case series ranges from 0.019% to
0.099%.1,29–31 The organism isolated in one study was Serra-
tia marcescens in two cases with a final visual outcome of no
light perception.29 However in30,31 two separate series,
reporting on cases of Haemophilus influenzae, or S. epide-
rmidis (2 cases) the patients had a final visual acuity of 20/
400 vision. Our case resulted in a final visual outcome of 4/
200.
In a report32 of 5 cases of severe acute intraocular inflam-
mation from 1278 cases that received intravitreal bev-
acizumab, 2 cases of Propionibacterium acnes, 1 case of
coagulase-negative Staphylococcus and 2 cases with no
microbial growth were detected from the vitreous aspirate.
In our case, Staphylococcus epidermidis was identified.
The risk of infectious endophthalmitis is always a concern
with any intraocular procedure. The most common sources
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lashes, and conjunctiva.33 Hence, thorough, standardized
cleansing techniques should help mitigate the incidence of
infectious endophthalmitis. Precautions against infection
tend to vary between studies and practitioners. The only
standard prophylactic measure is the use of preoperative
povidone–iodine drops and the use of a lid speculum. Preop-
erative povidone–iodine is recommended due to a previous
report of a significant reduction in endophthalmitis after pre-
operative use of povidone–iodine for intraocular surgery.34,35
The importance of a lid speculum, was determined by the
VISION36 trial that found two thirds of the 12 cases of
endophthalmitis were associated with protocol violations,
the most common being the lack of a lid speculum. The lid
speculum retracts the lid margin and lashes away from the
injection site, the general consensus is that lid speculum
use is an important step in reducing the risk of endophthalmi-
tis. Other prophylactic measures include instillation of topical
antibiotic postoperatively, wearing sterile gloves, and wear-
ing a mask during the procedure. In conclusion, although pre-
vious studies report a low incidence rate of endophthalmitis
after intravitreal injection of bevacizumab, it is still a concern
due to the potential for profound visual loss as our and pre-
vious reported cases have demonstrated. Informed consent
should incorporate the possibility of profound visual loss
after the procedure.References
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